Pricing Log in Create free account

Evommune Inc. (EVMN) vs Fate Therapeutics, Inc. (FATE)

Evommune Inc. and Fate Therapeutics, Inc. are both Biotechnology companies. Evommune Inc. and Fate Therapeutics, Inc. are of similar size ($241.3M and $223.1M). Evommune Inc. has the higher net margin (0.00% vs −1,941.1%) and the lower return on invested capital (−82.5% vs 0.00%). Across the 13 metrics below, Evommune Inc. leads on 7 and Fate Therapeutics, Inc. on 6.

Valuation

Metric EVMN FATE Biotechnology median
P/E n/m n/m 10.60
P/S n/m 34.13 9.40
P/B 0.87 1.44 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 14.04 9.02
Earnings yield (165.86%) (57.07%) (32.88%)
Free cash flow yield (31.07%) (47.59%) (23.13%)

Profitability

Metric EVMN FATE Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (2,058.08%) 0.00%
Net margin 0.00% (1,941.09%) 0.00%
Free cash flow margin 0.00% (1,624.06%) 0.00%
Return on equity (141.99%) (60.75%) (51.96%)
Return on assets (62.71%) (39.89%) (46.06%)
Return on invested capital (82.46%) 0.00% 0.00%

Growth

Metric EVMN FATE Biotechnology median
Revenue growth (TTM) — (23.36%) 6.76%
EPS growth (last fiscal year) 75.23% 29.88% 29.88%
Revenue growth, 5-year CAGR — (26.71%) 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric EVMN FATE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.68 4.85 4.97
Net debt to EBITDA 1.87 1.47 1.01

Dividend

Metric EVMN FATE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EVMN FATE Biotechnology median
Market cap 241.34m 223.08m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack